Cognition Therapeutics' Q3 2025 Financial Results and Clinical Program Progress: $30M Funding for Zervimesine Development and FDA Alignment on Registrational Path

Cognition Therapeutics reported Q3 2025 financial results, with $39.8 million in cash, cash equivalents, and restricted cash equivalents, and $36.3 million in obligated grant funds. The company completed a $30 million registered direct offering to support the next stage of development for Zervimesine (CT1812), achieved alignment with the FDA on a registration path for Alzheimer's disease, and expanded access program for Dementia with Lewy Bodies is ongoing.